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Most endogenous peptides are prone to fast metabolization by a broad variety of peptidase and protease enzymes that occur in different tissues and cells. As a result, a
main problem in peptidomics analysis is peptide degradation during the sampling step, including sampling storage and sample extraction, aiming at high recoveries for all
endogenous peptides present in a sample with no (further) breakdown of the proteins and peptides. Related problems are encountered during peptide functional and
receptor binding studies, where protease inhibitors are normally used to improve ligand stability against membrane bound enzymes.
EXPERIMENTAL
A general screening procedure to evaluate peptide metabolic stability
and protease inhibitor efficacy is described in Figure 1.
Sample matrices
Typically, plasma, crude tissue/cell homogenates or membrane fractions
are used as prepared for peptidomics analyses and in vitro experiments
such as radioligand binding and permeability studies. The preparation
may include a protease denaturation/removal treatment such as
microwave heating.
Protease activity testing
Model or target peptides are incubated at pH 7.4 in the sample matrix
under examination using a mixing block heater at 37°C. Aliquots are
withdrawn at suitable time points, and analyzed (after acidification,
heating and centrifugation) using HPLC with PDA and/or fluorescence
detection. Results are expressed as half-life times, calculated from the
curves obtained.
Protease inhibitor efficacy testing
Peptides are incubated under the same conditions as above, however in
absence (i.e. reference) and presence of selected protease inhibitors
(e.g. EDTA, leupeptin). At a pre-determined time point (e.g. half-life
without protease inhibitors), the reaction is stopped and the mixtures are
analyzed as described for protease activity testing. Half-life times are
calculated based upon first order kinetics assumption.
RESULTS AND DISCUSSION
CONCLUSIONS
• A simple general method can be applied for (a) testing the susceptibility of peptides to peptidase/protease activity in samples (derived from plasma, tissues and cells), (b)
verification of enzyme denaturation in sample preparation protocols, and (c) peptidase/protease activity inhibitor efficacy testing.
• A general protease inhibitor cocktail and EDTA were found improve the metabolic stability of obestatin in brain homogenates.
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Figure 1. General scheme for peptide stability and protease inhibitor efficacy testing
Typical HPLC conditions: Everest C18 238EV54 (250 mm × 4.6 mm, 300 Å, 5 µm) column (Grace Vydac) at 30°C, with (A) 0.1% formic acid in water, and (B) 0.1% formic 
acid in acetonitrile. The gradient used for the separation was: 95% A + 5% B from 0 to 5 minutes, followed a linear ramp from 5 to 65 min going to 70% A + 30% B. The flow 
rate was set at 1.0 ml/min [1].
Typical results are presented here. Other peptides and sample treatments were successfully analyzed using in the same methodology (data not given).
Stability of model peptides upon acidification and heat treatment was demonstrated.
The degradation of mouse obestatin in crude mouse brain homogenate () and mouse brain membranes
homogenate (), at a peptide/tissue-protein ratio of 1:10 m/m, is described in Figure 2. It was found that
this peptide is rapidly degraded when in contact with brain proteases and peptidases. The metabolization
half-lives were found to differ by a factor 1.4: 19.3 min and 27.4 min, resp.
Results obtained on protease inhibitors are presented in the Table below. Similarly increased half-lives
for both  homogenates were observed for EDTA (metal chelator) and a mixture of six protease inhibitors:
4-(2-aminoethyl)benzenesulfonyl fluoride (AEBSF), pepstatin A, E-64, bestatin, leupeptin, and aprotinin.
Protease inhibitor
Half-life (min)
Crude brain homogenate Brain membranes homogenate
UV FL UV FL
None (i.e. reference) 19 19 27 27
P8340 Protease Inhibitor Cocktail 52 54 74 77
EDTA 38 40 57 67
Soybean Trypsin Inhibitor 20 21 37 40
APMSF 20 21 15 17
1,10-Phenanthrolin 24 24 27 29
Captopril 20 20 27 30
Chymostatin 17 17 28 30 Figure 2. Degradation of mouse obestatin in brain homogenates
